All In Biotech

Free tool

FAERS Monitor: Durysta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211911 or its brand name (Durysta, Bimatoprost). Reports on generic versions are filed under their own applications.

Reports

2,818

Serious

1,650

59% of reports

Hospitalization

669

Death reported

129

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective268
  • intraocular pressure increased113
  • ocular hyperaemia108
  • no adverse event107
  • eye irritation93
  • eye pain92
  • nausea80
  • dyspnoea78
  • vision blurred73
  • diarrhoea71
  • fatigue71
  • headache71
  • madarosis61
  • off label use61
  • dizziness57

Reports by year received

View as table
YearReports
200410
20054
20068
200712
200821
200922
201023
201136
201221
201351
201465
201582
2016119
2017207
2018180
2019198
2020237
2021299
2022232
2023299
2024238
2025238
2026216

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intraocular pressure increasedSignal11366.655.57,173
madarosisSignal6139.430.72,236
ocular hyperaemiaSignal10817.014.11,613
eye painSignal9212.210.0935
eye irritationSignal9312.19.9935
no adverse eventSignal1074.43.7281
vision blurredSignal734.03.2160
drug ineffective2681.51.450
dyspnoea781.00.80
dizziness570.90.71
headache710.80.72
diarrhoea710.80.73
nausea800.80.66
fatigue710.70.511
off label use610.50.428

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.